



Supplementary Figure 6. HER2 levels post-treatment. PDX12 (a-d) and PDX8 (f-i) tumors (described in Supplementary Fig. 4) were assayed for HER2 via IHC. Representative HER2 IHC images are presented to compare treatment groups. Note T-DM1-treated PDX12 (c-d) and PDX8 (h-i) tumors express lower HER2 levels. Note single agent ABT-737 similar to single agent ABT-263 (Fig. 6), upregulates PDX12 HER2 levels (b). HER2 levels were quantified via H-score assessment (37). Data were summarized across multiple tumors from PDX12 (e) and PDX8 (j) experiments (Mann-Whitney one-tail test PDX12: vehicle versus ABT-737; p value = 0.0286, vehicle versus T-DM1; p value = 0.0286, vehicle versus T-DM1 + ABT-737; p value = 0.0286 and PDX8: vehicle versus T-DM1; p value = 0.0143, vehicle versus T-DM1 + ABT-737; p value = 0.0079). p values ≤ 0.05 (*) or ≤ 0.01 (**) are indicated as numerical values. Each line represents the median. Scale bar, $\sim 80 \mu\text{m}$.